# Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC

Source: https://onco.cc/trials/nct07150949/  
OnCo record `nct07150949` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine, celecoxib and serplulimab in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) is a phase 2, randomised interventional study registered as NCT07150949 by Fudan University, with a registry enrolment figure of 138 participants, started 2025-08-28 and due to reach its primary completion in 2027-08-31. Interventions recorded: Long-course radiotherapy; Oxaliplatin; Capecitabine; Celecoxib; Short-course radiotherapy; Serplulimab. Conditions listed: Locally Advanced Rectal Cancer; Neoadjuvant Therapy. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07150949
- Phase: 2
- Setting: A Prospective Randomized Phase II Trial of Long-Course Chemoradiotherapy or Short-Course Radiotherapy Combined With CAPOX, PD-1 Antibody, and a COX-2 Inhibitor for Microsatellite Stable Locally Advanced Rectal Cancer (SERRAC)
- Sponsor: Fudan University
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07150949: https://clinicaltrials.gov/study/NCT07150949

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Celecoxib](https://onco.cc/drugs/celecoxib/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07150949.json